Business
Landmark RATULS Research Trial of Robot-Assisted Stroke Therapy Utilizes BIONIK’s InMotion Robotic Therapy Systems
Landmark RATULS Research Trial of Robot-Assisted Stroke Therapy Utilizes BIONIK’s InMotion Robotic Therapy Systems.
About this update from Bionik Laboratories Corp.
[{"type":"text","content":"\n \n BIONIK \n Laboratories Corp. (OTCQB: BNKL) (\"BIONIK\" or the \n \"Company\"), a robotics company focused on providing rehabilitation and \n assistive technology solutions to individuals with neurological and \n mobility challenges from hospital to home, today announced the \n completion of a landmark Robot \n Assisted Training for the Upper Limb after Stroke (RATULS) trial \n utilizing the Company’s InMotion Robotic Therapy Systems.\n \n \n Results of the RATULS trial were presented at the European Stroke \n Organisation Conference (ESOC) in Milan, Italy on May 22, 2019 and \n published in the Lancet Online Journal on the same day. The study’s \n purpose was to compare clinical effectiveness of robot assisted \n training, enhanced upper limb therapy, and usual care for patients with \n moderate or severe upper limb functional limitation. The RATULS trial \n began in 2014 and was completed end of 2018.\n \n \n “We are pleased that the RATULS trial confirmed the finding of previous \n research studies which demonstrated that robot-assisted therapy improved \n upper limb impairment when compared with conventional care methods for \n stroke victims. The trial’s finding that robotic therapy is the only \n therapy to statistically maintain a significant impairment advantage at \n six months after treatment is a strong signal that robotic therapy is \n critical for achieving positive patient outcomes,” said Dr. Eric \n Dusseux, CEO, BIONIK Laboratories. “BIONIK’s InMotion Robotic Therapy \n Systems have been selected for some of the largest interventional \n research studies over the past 10 years, including the Veterans Affairs \n Robotics Trial which confirmed robot-assisted therapy improvement in \n upper limb impairment using the Fugl-Meyer Assessment (FMA), a \n stroke-specific, performance-based impairment index. In the VA study, \n the impairment advantage achieved through robot-assisted therapy \n translated into significant upper limb function improvements using the \n Wolf Motor Function Test.”\n \n \n For the RATULS trial, the primary outcome for upper limb success was \n determined by Action Research Arm Test (ARAT), with four distinct \n success criteria that varied according to baseline severity, not used \n previously and developed by the RATULS trial team. Although ...